Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...
Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...
Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Abbott issued a medical device correction for some ...
The decision to recall approximately three million sensors follows reports of potentially life-threatening errors in the devices. The malfunction causes the sensors to deliver incorrect low glucose ...
Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that a number of them may be ...
Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback